On Tuesday trading session, Nifty Pharma index added a percent amid positive market global cues. The slowdown in Covid-19 cases and rapid vaccination drive uplift sentiments for investors. Also, June 2021 healthy quarterly result expectations further boosted the sentiments due to huge demand in the sector for tackling the pandemic.
Although, according to the latest reports, Delta variant of Covid-19 is a matter of concern for the investors in viewing markets outlook as economic recovery prospects may take a toll.
During early trading deals, at around 11:20 AM, Nifty Pharma was trading at 14,510.35 up 138.15 points or 0.96%, touching a high of 14,515.70 and low of 14,372.70 during intraday trade on Tuesday
On the index,
Sun Pharma performed as a top bull surging by nearly 3% at Rs686.95 per piece followed by
Torrent Pharma and Aurobindo Pharma gaining by 1.25% and 1.24% respectively.
Heavyweight
Lupin was also trading over 1% at Rs1,164 per piece on the index.
Divis Lab and Cipla doing well by surging 0.44% and 0.42% respectively to lead the gains while Cadila, Biocon and Dr Reddys were also marginally higher.
On the contrary,
Alkem Labs was the lone laggard plunging by 0.47% on the index.
According to Ministry of Health and Family Welfare data, India’s Cumulative Recoveries crosses 3 cr mark and National Cumulative COVID-19 Vaccination Coverage exceeds 37.73 cr today.
Meanwhile, India reports 31,443 new cases in the last 24 hours, lowest in 118 days.